Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Stuart Hossack"'
Autor:
Nathan Gale, Mike McEwan, Alison C. Eldridge, Neil Sherwood, Edward Bowen, Simon McDermott, Emma Holmes, Andrew Hedge, Stuart Hossack, Oscar M. Camacho, Graham Errington, John McAughey, James Murphy, Chuan Liu, Christopher J. Proctor, Ian M. Fearon
Publikováno v:
BMC Public Health, Vol 17, Iss 1, Pp 1-18 (2017)
Abstract Background Smoking is a leading cause of numerous human disorders including lung cancer, chronic obstructive pulmonary disease, and atherosclerotic cardiovascular disease. The development of modified risk tobacco products (MRTPs) has been su
Externí odkaz:
https://doaj.org/article/262416f1d095480c9feef5dc6351bd08
Autor:
Paolo Mulatero, Michael Groessl, Bruno Vogt, Christoph Schumacher, Ronald Edward Steele, Ashley Brooks, Stuart Hossack, Hans‐Rudolf Brunner
Publikováno v:
British Journal of Clinical Pharmacology.
Autor:
Oscar M. Camacho, Simon McDermott, John McAughey, Chuan Liu, Emma Holmes, Graham Errington, Stuart Hossack, James Murphy, Edward Bowen, Alison Eldridge, Mike McEwan, Ian M. Fearon, Andrew Hedge, Christopher Proctor, Nathan Gale, Neil Sherwood
Publikováno v:
BMC Public Health, Vol 17, Iss 1, Pp 1-18 (2017)
BMC Public Health
BMC Public Health
Background Smoking is a leading cause of numerous human disorders including lung cancer, chronic obstructive pulmonary disease, and atherosclerotic cardiovascular disease. The development of modified risk tobacco products (MRTPs) has been suggested a
Autor:
Andrew Griffin, Stuart Hossack, Richard L. Leff, Dan A. Chiche, Philippe Walker, Roxane Aubray, William Brown
Publikováno v:
The Journal of Pain. 18:726-738
Most previous transient receptor potential vanilloid subtype 1 (TRPV1) antagonist programs have been put on hold, mainly because of on-target adverse events: hyperthermia and impaired noxious heat sensation. NEO6860 is a TRPV1 antagonist, blocking ca
Autor:
Neil Sherwood, Chuan Liu, James Glew, Simon McDermott, Emma Holmes, Nathan Gale, Andrew Hedge, Stuart Hossack, Louise Wakenshaw, Edward Bowen, Ian M. Fearon, Mike McEwan, Christopher Proctor, Graham Errington, Alison Eldridge, Oscar M. Camacho, John McAughey, James Murphy
Publikováno v:
Nicotine & Tobacco Research
Background Smoking is a leading cause of numerous human disorders including pulmonary disease, cardiovascular disease, and cancer. Disease development is primarily caused by exposure to cigarette smoke constituents, many of which are known toxicants.
Autor:
Mark Voskoboynik, Hendrik-Tobias Arkenau, Alastair Greystoke, Karen So, Ruth Plummer, Nicola Steele, Raffaele Califano, Emma Dean, Dana Ghiorghiu, Fiona H Blackhall, Stuart Hossack, Colin R Lindsay, Angela W. Dymond, Noor Md Haris, Yvonne Summers
Publikováno v:
British Journal of Cancer
Dean, E, Steele, N, Arkenau, H-T, Blackhall, F, Lindsay, C, Saggese, M, Califano, R, Greystoke, A, Voskoboynik, M, Ghiorghiu, D, Dymond, A, Smith, I & Plummer, R 2017, ' SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. ', British Journal of Cancer, pp. 938-946 . https://doi.org/10.1038/bjc.2017.271
Dean, E, Steele, N, Arkenau, H-T, Blackhall, F, Lindsay, C, Saggese, M, Califano, R, Greystoke, A, Voskoboynik, M, Ghiorghiu, D, Dymond, A, Smith, I & Plummer, R 2017, ' SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. ', British Journal of Cancer, pp. 938-946 . https://doi.org/10.1038/bjc.2017.271
BACKGROUND: We investigated selumetinib (AZD6244, ARRY-142886), an oral, potent, and highly selective, allosteric MEK1/2 inhibitor, plus platinum-doublet chemotherapy for patients with advanced/metastatic non-small cell lung cancer.METHODS: In this P
Autor:
Carmen Cuffari, Alena Y Z Edwards, David M. Pierce, Stuart Hossack, Hong Wan, Patrick Martin, Heather Van Heusen, Krzysztof Fyderek, Bartosz Korczowski
Publikováno v:
Drug Design, Development and Therapy
Carmen Cuffari,1 David Pierce,2 Bartosz Korczowski,3 Krzysztof Fyderek,4 Heather Van Heusen,5 Stuart Hossack,6 Hong Wan,5 Alena YZ Edwards,7 Patrick Martin5 1Department of Pediatrics, Division of Pediatric Gastroenterology and Nutrition, The Johns Ho
The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol
Autor:
Antoine Robinson, Michael Smyth, Lynne Poole, Heather Van Heusen, Patrick Martin, David M. Pierce, Stuart Hossack
Publikováno v:
Nephrology Dialysis Transplantation
Background. Lanthanum carbonate and sevelamer carbonate are non-calcium-based phosphate binders used to manage hyperphosphataemia in patients with chronic kidney disease (CKD). Patients with CKD may require intravenous or oral active vitamin D. We in
Autor:
Igor Ivanisevic, Stephen R. Byrn, David Engers, Jonathan Jimenez-Novoa, Ann Newman, Cheryl Campbell, Philip Gent, John Thomson, Jing Teng, Alison Templeton, Stuart Hossack
Publikováno v:
Journal of Pharmaceutical Sciences. 99:3901-3922
A solid-state approach to enable compounds in preclinical development is used by identifying an amorphous solid dispersion in a simple formulation to increase bioavailability. Itraconazole (ITZ) was chosen as a model crystalline compound displaying p
Autor:
Patrick Martin, Stuart Hossack, David M. Pierce, Mieke Hoppenbrouwers, Maria Velinova, Mary Corcoran
Publikováno v:
Drug Design, Development and Therapy
David Pierce,1 Mary Corcoran,2 Maria Velinova,3 Stuart Hossack,4 Mieke Hoppenbrouwers,5 Patrick Martin,21Shire, Basingstoke, UK; 2Shire, Wayne, PA, USA; 3PRA International, Zuidlaren, the Netherlands; 4Covance, Leeds, UK; 5Shire-Movetis NV, Turnhout,